Award recognizes the groundbreaking science of Dupixent and its transformational impact on multiple rare and common allergic and atopic conditions First and only therapy to specifically target the IL-4 and IL-13 signaling pathway, a key driver of type 2 inflammation that contributes to multiple conditions TARRYTOWN, N.Y., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Dupixent® (dupilumab) has been recognized as the “Best Biotechnology Product” of 2025 ...